Your browser is no longer supported. Please, upgrade your browser.
Delcath Systems, Inc.
Index- P/E- EPS (ttm)-112.56 Insider Own0.60% Shs Outstand6.59M Perf Week-11.70%
Market Cap67.61M Forward P/E- EPS next Y-3.46 Insider Trans- Shs Float5.02M Perf Month-25.60%
Income-24.20M PEG- EPS next Q-0.98 Inst Own42.30% Short Float7.19% Perf Quarter-51.92%
Sales1.60M P/S42.26 EPS this Y97.60% Inst Trans8.74% Short Ratio1.28 Perf Half Y-10.39%
Book/sh4.47 P/B2.30 EPS next Y13.70% ROA-118.90% Target Price- Perf Year28.25%
Cash/sh4.34 P/C2.36 EPS next 5Y15.00% ROE-386.60% 52W Range7.15 - 25.18 Perf YTD-42.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-61.28% Beta0.57
Dividend %- Quick Ratio3.10 Sales past 5Y-1.20% Gross Margin61.10% 52W Low36.36% ATR0.91
Employees43 Current Ratio3.20 Sales Q/Q0.00% Oper. Margin- RSI (14)30.19 Volatility7.03% 6.35%
OptionableNo Debt/Eq0.09 EPS Q/Q-100.40% Profit Margin- Rel Volume0.73 Prev Close10.26
ShortableYes LT Debt/Eq0.00 EarningsMay 11 BMO Payout- Avg Volume282.16K Price9.75
Recom1.50 SMA20-17.27% SMA50-34.64% SMA200-32.46% Volume22,995 Change-4.97%
Mar-09-21Initiated Canaccord Genuity Buy $24
Jan-05-21Initiated BTIG Research Buy $23
Jun-01-20Initiated Laidlaw Buy $19
May-11-21 08:00AM  
May-03-21 02:33AM  
Apr-30-21 04:01PM  
Apr-21-21 08:38AM  
Mar-31-21 02:55PM  
Mar-24-21 04:01PM  
Mar-08-21 09:00AM  
Feb-11-21 09:00AM  
Jan-11-21 10:56AM  
Dec-11-20 10:31AM  
Dec-09-20 08:00AM  
Dec-08-20 04:01PM  
Dec-07-20 07:30AM  
Nov-11-20 08:00AM  
Nov-02-20 04:01PM  
Oct-29-20 07:30AM  
Oct-01-20 04:07PM  
Sep-28-20 10:50AM  
Sep-10-20 09:00AM  
Sep-02-20 05:36PM  
Aug-25-20 04:01PM  
Aug-13-20 04:01PM  
Aug-06-20 04:01PM  
Aug-05-20 09:00AM  
Aug-03-20 01:48PM  
May-26-20 08:30AM  
May-19-20 08:30AM  
May-15-20 06:30AM  
May-05-20 04:05PM  
May-01-20 10:17AM  
Feb-19-20 08:30AM  
Jan-13-20 08:30AM  
Dec-19-19 08:30AM  
Dec-03-19 08:30AM  
Oct-22-19 07:27AM  
Oct-18-19 08:00AM  
Oct-15-19 08:00AM  
Oct-08-19 08:00AM  
Sep-23-19 11:30AM  
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MICHEL GERARD JChief Executive OfficerApr 05Buy12.8815,500199,64023,000Apr 05 12:34 PM
MICHEL GERARD JChief Executive OfficerDec 11Buy13.257,50099,3757,500Dec 14 02:00 PM
Purpura JohnChief Operating OfficerNov 19Buy12.681,60020,28814,713Nov 20 04:05 PM
SALAMON STEVEN A JDirectorNov 17Buy12.112,50030,280189,500Nov 17 12:37 PM
Rosalind Advisors, Inc.DirectorNov 17Buy12.112,50030,280191,500Nov 19 02:27 PM
Aharon GilDirectorNov 16Buy12.002,00024,000187,000Nov 16 01:20 PM
Rosalind Advisors, Inc.DirectorNov 13Buy11.754,00047,000189,000Nov 16 01:21 PM
SALAMON STEVEN A JDirectorNov 13Buy11.512,00023,020187,000Nov 13 01:43 PM